Abstract
Cannabidiol (CBD), a non-psychoactive phytochemical derived from the hemp plant, has emerged as a promising alternative therapy for chronic pain and inflammation. Unlike tetrahydrocannabinol (THC), CBD does not produce psychotropic effects, making it a safer option for various populations. This article explores the therapeutic potential of CBD, particularly in the context of chronic inflammation and pain, and discusses its relevance in physical therapy practice. Issues related to dosing, bioavailability, and product quality are also addressed, along with current limitations in topical application research.
Â
Introduction
Chronic pain and inflammation are significant clinical challenges affecting millions globally. Conventional pharmacologic treatments such as non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are often associated with adverse side effects and risk of dependency. In recent years, cannabidiol (CBD) has gained attention for its analgesic and anti-inflammatory properties. Derived from the hemp plant, CBD offers a natural and generally well-tolerated alternative to traditional pain management therapies.
Â
 CBD: An Overview
CBD is one of over 100 cannabinoids identified in Cannabis sativa. Unlike THC, the principal psychoactive compound in cannabis, CBD exerts its therapeutic effects without causing intoxication. Research suggests that CBD interacts with the endocannabinoid system (ECS), modulating inflammation and nociception through multiple pathways, including TRPV1 receptor agonism and inhibition of adenosine uptake1.
Â
 Clinical Relevance in Chronic Pain and Inflammation
Inflammation is a critical physiological response that promotes healing following tissue injury. However, when inflammation becomes prolonged—typically persisting beyond three months—it can lead to chronic pain and tissue dysfunction2. In physical therapy and rehabilitative contexts, managing chronic inflammation is essential for facilitating recovery and improving patient outcomes.
CBD has demonstrated efficacy in modulating inflammatory responses and reducing neuropathic and musculoskeletal pain, suggesting it may be a beneficial adjunct in treating conditions such as arthritis, fibromyalgia, and chronic low back pain. Its natural origin, favorable safety profile, and potential to mitigate pain without gastrointestinal, renal, or addictive risks associated with NSAIDs and opioids make it a compelling alternative3.
Â
Dosing and Product Considerations
A common issue among users is the perception that CBD lacks efficacy. This is often attributable to subtherapeutic dosing and mislabeling of commercial products. Due to limited regulation, many over-the-counter CBD products do not contain the concentrations advertised on their labels4.
Clinical studies suggest that analgesic and anxiolytic effects are more consistently observed at oral doses between 300–400 mg/day without significant adverse effects5. However, lower doses—starting at approximately 40 mg/day—may also provide therapeutic benefit depending on individual sensitivity and the specific condition treated6.
To enhance absorption and minimize first-pass hepatic metabolism, oral CBD should be taken with a high-fat meal. Co-administration with medium-chain triglyceride (MCT) oil, often derived from coconut oil, may further improve bioavailability and provide additional nutritional benefits7.
Â
Topical Applications
Topical administration of cannabidiol (CBD) offers a promising, localized approach to managing pain and inflammation with minimal systemic side effects. Unlike oral or inhaled forms, topical CBD is applied directly to the skin, allowing it to interact with cannabinoid receptors in the peripheral nervous system and local tissues. This can be particularly advantageous for targeting joint pain, muscle soreness, and localized inflammatory conditions.
While much of the public enthusiasm surrounding topical CBD is based on anecdotal reports and consumer testimonials, a growing body of preclinical and early clinical research supports its potential therapeutic benefits. Animal models have demonstrated that transdermal CBD can significantly reduce inflammation and pain behaviors. For instance, Hammell et al. (2016) found that transdermal CBD reduced joint swelling, pro-inflammatory markers, and pain-related behaviors in a rat model of arthritis, without evident side effects8. Similarly, Xu et al. (2020) observed that topical CBD attenuated inflammatory pain and hypersensitivity in rodent models, showing promise as a localized anti-inflammatory agent9.
Emerging clinical evidence is beginning to support these findings in human subjects. In a small double-blind, placebo-controlled trial, Xu et al. (2019) reported that topical CBD gel reduced pain and other symptoms in patients with peripheral neuropathy of the lower extremities, without serious adverse events10. Another pilot study by Verrico et al. (2020) examined CBD’s effect in individuals with temporomandibular disorder (TMD) and found significant improvements in muscle tenderness and jaw function following topical application11.
Despite these promising findings, more large-scale, placebo-controlled human trials are necessary to determine optimal formulations, dosing, absorption mechanisms, and long-term efficacy. The variability in commercial CBD products—including differences in concentration, formulation (e.g., gels, balms, creams), and bioavailability—adds complexity to assessing consistent outcomes. Factors such as skin permeability, carrier oils, and the presence of additional active ingredients (like menthol or capsaicin) may also influence effectiveness and need further exploration.
In summary, while preliminary studies and real-world reports suggest that topical CBD holds therapeutic promise for managing localized pain and inflammation, rigorous clinical research is still required to establish best practices and standardized treatment protocols.
Conclusion
CBD represents a promising, naturally derived compound with significant potential for the management of chronic pain and inflammation. Its role in physical therapy and integrative medicine continues to grow as clinicians seek alternatives to NSAIDs and opioids. However, more rigorous clinical research is necessary to standardize dosing, improve product quality, and better understand its mechanisms of action—especially for topical applications. With responsible use and appropriate guidance, CBD may serve as an effective adjunct in the comprehensive treatment of chronic musculoskeletal conditions.
Â
References
1. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2007;556(1-3):75-83.
2. Mustoe TA, O’Shaughnessy K, Kloeters O. Chronic wound pathogenesis and current treatment strategies: a unifying hypothesis. Plast Reconstr Surg. 2006;117(7 Suppl):35S - 41S.
3. Urits I, Gress K, Charipova K, et al. Use of cannabidiol (CBD) for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol. 2020;34(3):463-477.
4. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708-1709.
5. Arnold JC, McCartney D, Suraev A, McGregor IS. The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clin Transl Sci. 2023;16(1):10-30.
6. Bhaskar A, Bell A, Boivin M, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021;3(1):22.
7. Mozaffari K, Willette S, Lucker BF, Kovar SE, Holguin FO, Guzman I. The effects of food on cannabidiol bioaccessibility. Molecules. 2021;26(12):3573.
8. Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016;20(6):936-948.
9. Xu DH, Cullen BD, Tang M, Fang Y. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol. 2020;21(5):390-402.
10. Xu DH. Topical cannabidiol for the treatment of peripheral neuropathy: A randomized, double-blind, placebo-controlled study. Pain Medicine. 2019;20(5):953-961.
11. Verrico CD, Wesson S, Konduri V, et al. A randomized controlled trial of topical cannabidiol for the treatment of temporomandibular disorder myofascial pain. Journal of the American Dental Association. 2020;151(8):600-608.
